[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021004191A - Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. - Google Patents

Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.

Info

Publication number
MX2021004191A
MX2021004191A MX2021004191A MX2021004191A MX2021004191A MX 2021004191 A MX2021004191 A MX 2021004191A MX 2021004191 A MX2021004191 A MX 2021004191A MX 2021004191 A MX2021004191 A MX 2021004191A MX 2021004191 A MX2021004191 A MX 2021004191A
Authority
MX
Mexico
Prior art keywords
bifunctional compounds
proteosome pathway
ubiquitin proteosome
degrading
via ubiquitin
Prior art date
Application number
MX2021004191A
Other languages
English (en)
Inventor
Joel Mcintosh
Jeffrey Wu
Ge Peng
Daniel W Robbins
Arthur T Sands
Jeffrey Mihalic
Daisuke Kato
Dahlia Weiss
Original Assignee
Nurix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurix Therapeutics Inc filed Critical Nurix Therapeutics Inc
Publication of MX2021004191A publication Critical patent/MX2021004191A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos útiles para degradar a BTK mediante una trayectoria proteolítica de ubiquitina. La invención también proporciona composiciones farmacéuticamente aceptables que comprenden tales compuestos y métodos para usar las composiciones en el tratamiento de varias enfermedades, condiciones, o trastornos.
MX2021004191A 2018-10-15 2019-10-14 Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. MX2021004191A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862745786P 2018-10-15 2018-10-15
US201862767819P 2018-11-15 2018-11-15
US201962836398P 2019-04-19 2019-04-19
US201962887812P 2019-08-16 2019-08-16
US201962901984P 2019-09-18 2019-09-18
PCT/US2019/056112 WO2020081450A1 (en) 2018-10-15 2019-10-14 Bifunctional compounds for degrading btk via ubiquitin proteosome pathway

Publications (1)

Publication Number Publication Date
MX2021004191A true MX2021004191A (es) 2021-05-27

Family

ID=68425337

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021004191A MX2021004191A (es) 2018-10-15 2019-10-14 Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
MX2024008539A MX2024008539A (es) 2018-10-15 2021-04-09 Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024008539A MX2024008539A (es) 2018-10-15 2021-04-09 Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.

Country Status (11)

Country Link
US (3) US11479556B1 (es)
EP (1) EP3867242A1 (es)
JP (1) JP2022508705A (es)
KR (1) KR20210077719A (es)
CN (1) CN113412259B (es)
AU (2) AU2019360928B2 (es)
BR (2) BR122023024103A2 (es)
CA (1) CA3115526A1 (es)
IL (1) IL281904A (es)
MX (2) MX2021004191A (es)
WO (1) WO2020081450A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
RU2020124138A (ru) 2017-12-22 2022-01-24 Хиберселл, Инк. Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
EP3773576A4 (en) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
BR122023024103A2 (pt) 2018-10-15 2024-02-20 Nurix Therapeutics, Inc. Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos
WO2020210508A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
CN114206855A (zh) 2019-05-17 2022-03-18 紐力克斯治疗公司 用于Cbl-b抑制的氰基环丁基类化合物及其用途
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN114364670A (zh) 2019-06-26 2022-04-15 纽力克斯治疗公司 用于Cbl-b抑制的取代苄基-三唑类化合物及其进一步用途
EP4034140A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for use in adoptive cell therapy
CA3160713A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
KR20230008176A (ko) * 2020-05-06 2023-01-13 누릭스 테라퓨틱스 인코포레이티드 조혈 전구세포 키나아제의 이작용성 분해제 및 이의 치료적 용도
JP2023549341A (ja) 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
WO2022120355A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
KR20230167407A (ko) 2021-04-08 2023-12-08 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제제 화합물을 이용한 조합 요법
EP4361153A1 (en) 2021-06-25 2024-05-01 Korea Research Institute of Chemical Technology Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
KR102637915B1 (ko) * 2021-06-25 2024-02-19 한국화학연구원 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
US20240360146A1 (en) * 2021-07-01 2024-10-31 Hangzhou Healzen Therapeutics Co., Ltd. Bruton's tyrosine kinase and mutant degrader, composition and application thereof
EP4367112A1 (en) 2021-07-09 2024-05-15 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
EP4370123A1 (en) 2021-07-14 2024-05-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk with diminished imid activity
JP2024526984A (ja) 2021-07-23 2024-07-19 ニューリックス セラピューティクス，インコーポレイテッド 増進されたＩＭｉＤ活性を伴ってＢＴＫを分解するための二官能性化合物
WO2023009709A1 (en) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Pyrazolo piperazines as jak2 inhibitors
WO2023059582A1 (en) * 2021-10-04 2023-04-13 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
EP4422630A1 (en) * 2021-10-26 2024-09-04 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
MX2024005702A (es) * 2021-11-18 2024-06-26 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivado de imida fusionado.
CN116143757B (zh) * 2021-11-22 2024-07-05 杭州和正医药有限公司 一种可降解btk激酶的多功能化合物、组合物及应用
CN115894450B (zh) * 2021-11-30 2023-09-12 山东如至生物医药科技有限公司 一种新型多环类化合物及其组合物和用途
TW202340198A (zh) * 2022-01-28 2023-10-16 大陸商上海齊魯製藥研究中心有限公司 靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途
WO2023227080A1 (zh) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 一种protac化合物、含其的药物组合物及其制备方法和应用
WO2024043334A1 (ja) * 2022-08-26 2024-02-29 富士フイルム株式会社 新規なピペラジン誘導体又はその塩及び医薬組成物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054355A1 (en) 2003-03-05 2007-03-08 Yuval Reiss Cbl-b polypeptides, complexes and related methods
WO2007072225A2 (en) 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
ES2566502T3 (es) 2006-09-13 2016-04-13 The Trustees Of Columbia University In The City Of New York Agentes y métodos para provocar una respuesta inmune antitumoral
AT506041A1 (de) 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
PL2242749T3 (pl) 2008-02-05 2013-09-30 Hoffmann La Roche Nowe pirydynony i pirydazynony
CN102458402B (zh) * 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
SG185462A1 (en) 2010-05-07 2012-12-28 Gilead Connecticut Inc Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2471548A1 (de) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
US20130110678A1 (en) 2011-11-02 2013-05-02 Apple Inc. Purchasing a product in a store using a mobile device
RU2622391C2 (ru) 2011-11-03 2017-06-15 Ф. Хоффманн-Ля Рош Аг Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX358660B (es) 2012-01-12 2018-08-30 Univ Yale Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
JP2015531781A (ja) 2012-09-13 2015-11-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
JP6345786B2 (ja) * 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2016196776A2 (en) 2015-06-02 2016-12-08 Pharmacyclics Llc. Inhibitors of bruton's tyrosine kinase
ES2793014T3 (es) 2015-07-17 2020-11-12 Takeda Pharmaceuticals Co Derivados de oxadiazol útiles como inhibidores de HDAC
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
EP3544975B1 (en) * 2016-11-22 2022-01-05 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and use
EP3551185A4 (en) * 2016-12-08 2021-07-14 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US20220324835A1 (en) 2018-01-26 2022-10-13 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
BR122023024103A2 (pt) 2018-10-15 2024-02-20 Nurix Therapeutics, Inc. Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos
EP3924350A1 (en) 2019-02-13 2021-12-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2020210508A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
CN114206855A (zh) 2019-05-17 2022-03-18 紐力克斯治疗公司 用于Cbl-b抑制的氰基环丁基类化合物及其用途
CN114364670A (zh) 2019-06-26 2022-04-15 纽力克斯治疗公司 用于Cbl-b抑制的取代苄基-三唑类化合物及其进一步用途
EP4003965A1 (en) 2019-07-30 2022-06-01 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
EP4034140A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for use in adoptive cell therapy
WO2021091575A1 (en) 2019-11-08 2021-05-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CA3160713A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
EP4370123A1 (en) 2021-07-14 2024-05-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk with diminished imid activity
JP2024526984A (ja) 2021-07-23 2024-07-19 ニューリックス セラピューティクス，インコーポレイテッド 増進されたＩＭｉＤ活性を伴ってＢＴＫを分解するための二官能性化合物
EP4422630A1 (en) 2021-10-26 2024-09-04 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Also Published As

Publication number Publication date
AU2019360928B2 (en) 2023-11-09
IL281904A (en) 2021-05-31
KR20210077719A (ko) 2021-06-25
CN113412259A (zh) 2021-09-17
CN113412259B (zh) 2024-07-16
WO2020081450A1 (en) 2020-04-23
AU2019360928A1 (en) 2021-05-13
US11479556B1 (en) 2022-10-25
US11866442B2 (en) 2024-01-09
JP2022508705A (ja) 2022-01-19
US20240124475A1 (en) 2024-04-18
EP3867242A1 (en) 2021-08-25
BR122023024103A2 (pt) 2024-02-20
AU2023266254A1 (en) 2023-12-07
US20230029378A1 (en) 2023-01-26
BR112021007115A2 (pt) 2021-07-20
MX2024008539A (es) 2024-07-19
CA3115526A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
MX2024008539A (es) Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
MX2022006672A (es) Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12017500724A1 (en) Carbazole derivatives
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
SI1853232T1 (sl) Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo
MX2022000712A (es) Moduladores de nlrp3.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2024000947A (es) Compuestos bifuncionales para degradar btk con actividad de imid mejorada.
MX2021008941A (es) Moduladores gpr35.
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
WO2023069514A9 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
MX2021008188A (es) Compuestos de anandamida.